What Are the Most Common GLP-1 Insurance Denial Reasons?

Reason by reason

"Not medically necessary"

Preauthorization is a decision by a health insurer or plan that a health care service, treatment plan, prescription drug, or durable medical equipment is medically necessary. A denial on this basis means your documentation did not meet the plan's written rules.

A notice of adverse benefit determination must describe the internal guidelines or criterion used in making the determination and inform the consumer that a copy of the internal requirements will be provided free of charge upon request. The notice must also describe any additional information needed to improve or complete the claim, and if the determination is based on a medical necessity, experimental treatment, or similar exclusion, it must provide either an explanation of the scientific or clinical judgment for the determination or a notice that such an explanation will be provided free of charge upon request.

A claimant has the right to a full and fair review, including the opportunity to review and respond with written comments, documents, and records to any evidence or rationale under consideration. An enrollee filing an internal appeal should submit any additional information they want the insurer to consider, such as a letter from the doctor.

"Non-formulary" or "not on the drug list"

A formulary is the list of prescription drugs covered by a prescription drug plan or other insurance plan offering prescription drug benefits.

An enrollee has the right to follow their insurance company's drug exceptions process, which allows them to get a prescribed drug not normally covered by their health plan. To get a drug covered through the exceptions process the enrollee's doctor must confirm to the health plan, orally or in writing, that the drug is appropriate for the enrollee's medical condition.

Three grounds carry an exception request: that all other drugs covered by the plan have not been or will not be as effective as the drug being requested; that any alternative drug covered by the plan has caused or is likely to cause side effects that may be harmful to the enrollee; or, where the plan limits the number of doses allowed, that the allowed dosage has not worked for the enrollee's condition.

While an enrollee is in the drug exceptions process, the plan may give them access to the requested drug until a decision is made. If a drug exception is granted, the health plan generally treats the drug as covered and charges the copayment that applies to the most expensive drugs already covered on the plan. Any amount an enrollee pays for a drug obtained through the exceptions process generally counts toward their deductible and maximum out-of-pocket limits.

"The benefit is not offered under your plan"

It is a contract question, not a chart question, but still formally appealable: a denial on the ground that the benefit is not offered under the enrollee's health plan can be appealed.

A notice of adverse benefit determination must describe the plan's or issuer's standard used to deny the claim.

The approved indication does not match your reason for taking the drug

FDA-approved indications differ sharply between brands, including brands that contain the same molecule.

• The Mounjaro FDA-approved indication is limited to glycemic control in type 2 diabetes mellitus; chronic weight management is not an approved indication under the Mounjaro label.
• All three OZEMPIC injection indications are restricted to adults with type 2 diabetes mellitus.
• Wegovy injection is indicated, in combination with a reduced calorie diet and increased physical activity, to reduce excess body weight in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.
• Zepbound (tirzepatide) is FDA-indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition. Both Zepbound indications are limited to adults; the safety and effectiveness of Zepbound have not been established in pediatric patients.

Form matters too. Zepbound is administered exclusively as a subcutaneous injection, and no oral dosage form of Zepbound is listed in the label. Wegovy is marketed in two distinct dosage forms under a single brand name and a single FDA label: WEGOVY (semaglutide) injection, solution, and WEGOVY (semaglutide) tablet. Prescribers must specify which form is intended, as dosing schedules and indications differ between them.

Medicare denials work differently

Since the inception of the Medicare Part D program, CMS has interpreted the statutory exclusion of 'agents when used for weight loss' to mean anti-obesity medications are coverable under Part D only when used for a medically accepted indication other than weight loss or weight management.

Through the Medicare GLP-1 Bridge, a short-term demonstration running from July 1, 2026 through December 31, 2027, eligible Medicare Part D beneficiaries can obtain certain GLP-1 medications, including Zepbound, for a $50 per month copay, unchanged regardless of Part D benefit phase. Only the Zepbound KwikPen formulation is included in the Medicare GLP-1 Bridge; the single-dose vial and single-dose pen formulations are not available through the program. Novo Nordisk states that all dose strengths of the Wegovy pen and pill are available for $50 per month to patients enrolled in an eligible Medicare Part D plan under the Medicare GLP-1 Bridge program, subject to prior authorization and a covered FDA-approved indication.

The clock and the escalation ladder

• Plans and issuers have 15 calendar days to make a pre-service (prior authorization) benefit determination.
• An insurer must notify the enrollee in writing of a denial within 72 hours for urgent care cases.
• An enrollee must file an internal appeal within 180 days (6 months) of receiving notice that the claim was denied.
• An internal appeal must be completed within 30 days if the appeal concerns a service the enrollee has not yet received.
• The group market may require one or two levels of internal appeal, while the individual market has one level.
• A plan must give its internal appeal decision within 72 hours after receiving the request when the appeal concerns a denial of a claim for urgent care.
• An enrollee must file a written request for an external review within four months after the date they receive a notice or final determination from the insurer that the claim has been denied.
• Standard external reviews are decided as soon as possible and no later than 45 days after the request was received.
• Expedited external reviews are decided as soon as possible and no later than 72 hours after the request was received, or less depending on the medical urgency of the case.
• The insurer is required by law to accept the external reviewer's decision.

An enrollee can file an expedited appeal if the timeline for the standard appeal process would seriously jeopardize their life or their ability to regain maximum function. Plans and issuers are required to provide continued coverage pending the outcome of an appeal — a rule narrower than it sounds: it protects an ongoing course of treatment the plan has already approved, not a drug the plan never approved. External review is free under the federal process; only states that expressly allowed a filing fee as of November 18, 2015 may still charge one, capped at $25 per external review.

The Affordable Care Act internal appeals and external review provisions apply only to health plans or policies created or purchased after March 23, 2010; grandfathered health plans are not covered. And as of July 1, 2026, the HHS-Administered Federal External Review Process (FERP) is temporarily unavailable for enrollees who live in Alabama, Florida, Georgia, Texas, Wisconsin, or a U.S. territory other than Puerto Rico and whose plan or issuer uses that process.

If the denial is not going to move

When the benefit is genuinely excluded, the remaining routes are cash-pay.

Measured's cash pay programs start at $119/month with medication and membership included, as of August 2026. As of August 2026, Measured lists Compounded Semaglutide as no-insurance-required with medication included in the membership price, from $119/mo. As of August 2026, Measured lists Compounded Tirzepatide as no-insurance-required with medication included in the membership price, from $219/mo. Compounded medications are not reviewed or approved by the FDA for safety or effectiveness.

Measured lists the Wegovy Pill (daily oral semaglutide) as requiring no insurance, with medication paid separately from membership. As of August 7, 2026, self-pay pricing for the Wegovy pill is advertised at $149 per month for the 1.5 mg and 4 mg doses, with the 4 mg price scheduled to rise to $199 per month after August 31, 2026. Measured states that membership fees, nutrition counseling copays, and eligible cash-pay medication expenses can typically be paid for or reimbursed through an HSA or FSA.

How this article was built

This page draws on three source sets, all read as of August 5, 2026: FDA prescribing information published on DailyMed, federal appeals and coverage rules published by HealthCare.gov and CMS, and Measured's own published help center and pricing pages. It omits a denial-reason distribution, overturn rates by reason, step-therapy specifics, Medicaid rules, and self-funded employer plan carve-outs; those are not in its source set.